Related Experiment Videos
Vitronectin receptors in vascular disorders.
1Albany College of Pharmacy, NY 12208-3492, USA. Mousas@acp.edu
Current Opinion in Investigational Drugs (London, England : 2000)
|September 5, 2002
Summary
Integrin antagonists show promise in treating diseases by blocking specific cell interactions. This review highlights alpha v integrin antagonists for vascular disorders like restenosis and angiogenesis.
Area of Science:
- Integrin biology and pharmacology
- Vascular medicine and pathology
Background:
- Integrin antagonists are a diverse class of molecules under clinical evaluation.
- Advanced integrin antagonists target platelet, leukocyte, and vascular integrins.
Purpose of the Study:
- To review the role of alpha v integrins (alpha v/beta3 and alpha v/beta5) in vascular disorders.
- To focus on angiogenesis-mediated disorders and vascular restenosis.
Main Methods:
- Literature review of clinical evaluations of integrin antagonists.
- Focus on the specific roles of alpha v integrin subtypes.
Main Results:
- Various integrin antagonist candidates have been clinically evaluated.
- Intravenous platelet alphaIIb/beta3, leukocyte alpha4/beta1, and vascular alpha v/beta3 antagonists are most advanced.
- Alpha v integrins are key players in vascular pathologies.
Conclusions:
- Alpha v integrins are critical targets for treating vascular disorders.
- Further research into alpha v integrin antagonists may yield new therapeutic strategies for angiogenesis-mediated disorders and restenosis.